Amaç: Kronik karaci¤er hastal›¤› olan olgularda karaci¤er dokusundaki fibrozis varl›¤›n›n ve miktar›n›n de¤erlendirilmesi; tedavi stratejisini, tedaviye yan›t› ve prognozu belirleyen en önemli etkendir. Bu çal›flman›n amac› karaci¤er fibrozisinin de¤erlendiril-mesinde proteomik analiz ile yeni biyolojik belirteçlerin araflt›r›lmas›d›r. Yöntem: Kronik karaci¤er hastal›¤› olan toplam 87 hasta (Metavir indeks ile, 17 F0, 30 F1, 6 F2, 9 F3 ve 21 F4) (using METAVIR index, 17 F0, 30 F1, 6 F2, 9 F3, and 21 F4 patients) 
INTRODUCTION
Hepatic fibrosis is a common feature of chronic liver diseases of different etiologies. It is associated with progression of liver disease, and its increase can herald complications of liver disease, including cirrhosis, hepatocellular carcinoma (HCC), end-stage liver disease, and death. Chronic hepatitis C and chronic hepatitis B are important causes of chronic liver disease and cirrhosis worldwide. The accurate assessment of the presence and severity of liver fibrosis is of paramount importance in determining management strategies, response to treatment and prognosis in patients with chronic liver disease.
Histological diagnosis and assessment of the degree of fibrosis with liver biopsy have long been the gold standard. However, it is an invasive procedure with inherent risk. Approximately 20% of patients have pain after the procedure. The risk of severe complications ranges from 0.3% to 0.5% (1) , and risk of mortality attributed to liver biopsy, although low (0.05%), exists (2) . Furthermore, biopsy is prone to sampling error, leading to 20-33% of false histological allocations, especially in patients with advanced liver disease (stage ≥F2 in the ME-TAVIR scale) (3) (4) (5) (6) . In addition, the use of suction needles is widespread and often results in tissue fragmentation, further complicating a reliable assessment (7) .
The search for noninvasive assessment of liver fibrosis started in the 1970s, and several noninvasive markers to detect liver fibrosis have been developed throughout the years (8) (9) (10) (11) (12) (13) (14) . Currently, noninvasive assessment of liver fibrosis involves not only serum markers but also a physical approach, transient elastography (TE), which measures stiffness of the liver (15) . Among the several serum markers, the most investigated and validated ones are the aspartate to platelet ratio index (APRI) and the FibroTest (16) . These tests and TE have been well validated in chronic hepatitis C but to a lesser extent in chronic hepatitis B. TE may be problematic in obese patients (17) , and may give overestimated scores in chronic hepatitis patients with active necroinflammation (18) . Serum levels of fibrosis markers related to the fibrogenic process, such as hyaluronic acid, may be confounded by associated diseases with fibrosis in other organs (16) .
Advances in high throughput proteomics technology have driven proteomics research into identification of effective biomarkers. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is a proteomic high-throughput technique, which has been improved with the progression of protein-chip systems. SELDI-based techniques together with bioinformatics have so far been successfully applied for early detection of several cancer types (19, 20) . In addition, SELDI-TOF MS has also been used to assess liver fibrosis and cirrhosis in patients with chronic hepatitis B virus (HBV) (21, 22) and chronic hepatitis C virus (HCV) infection (23, 24) . In the present study, we aimed to discover potential biomarkers in the serum samples of patients with HBV or HCV infection for assessment of liver fibrosis using SELDI-TOF MS.
MATERIALS AND METHODS

Samples
From January 2007 to May 2008, serum samples of 90 patients with chronic liver disease with available liver biopsy and 29 healthy controls (HCs) (19 males, 10 females; mean±SD age: 46.2±6.6) were collected at the Gastroenterology Department of Ankara University Medical School. Healthy subjects with normal serum levels of aminotransferases and alkaline phosphatase (ALP) were included in the study. These persons had no history of chronic liver disease. The study protocol was approved by the Ethics Committee of the Medical School of Ankara University on 22 January 2007 (registration number 106-2759). All patients gave informed consent. Blood samples were collected before liver biopsy on the same day. Serum samples were aliquoted and stored at -80°C until testing. None of the samples was thawed more than once. An experienced pathologist (EE), unaware of clinical data, evaluated all biopsy samples. Only samples of patients for whom reproducibility of liver fibrosis staging was confirmed by another pathologist (BS) were included in the study. Thus, seven patients were excluded from the study because of different biopsy evaluation results. Serum samples of 83 patients (53 patients with chronic hepatitis C, 30 patients with chronic hepatitis B) with pathological agreement were used in the study (35 males, 48 females; mean±SD age: 49.2±8.5). Hepatic fibrosis was assessed using the METAVIR index, which revealed F0 fibrosis in 17, F1 in 30, F2 in 6, F3 in 9, and F4 in 21 patients.
Serum Proteomic Profiling
To determine the best serum profiles with regard to number and resolution of the protein peaks, four chips with different ProteinChip surfaces (cationic, anionic, hydrophobic, and Cu metal binding; Ciphergen Biosystems, Fremont, CA, USA) were tested. For further analysis, the IMAC30 (Cu metal binding surface) protein chip, which displayed the best serum profile, was selected. Serum samples were first thawed completely, vortexed briefly, and centrifuged at 3500 g for 10 minutes (min) at 4°C to remove debris. Each serum sample was then denatured by the addition of U9 solution (9M urea, 2% CHAPS and 150 mM Tris-HCl, pH 9) in a 2:5 ratio, and mixed on a platform shaker for 30 min at 4°C. IMAC30 protein chip arrays were pre-equilibrated twice with 100 mM CuSO4 for 5 min, and washed three times with 1 mM HEPES (pH 7) for 2 min. Arrays were then incubated four times with 150 μl of the binding buffer (PBS 1X, 0.3 M NaCl, 0.1% Triton X-100) for 5 min. Then, 100 μl binding buffer was added to 2.5 μl U9-treated serum sample and applied randomly to a pre-activated protein chip array in duplicate for an incubation for 1 hour (h) on a shaker at room temperature. After incubation, each array was washed three times with binding buffer (5 min for each), and then without Tritonbinding buffer, and rinsed twice with 1 mM HE-PES. Finally, after air drying, 1 μl of a saturated solution of sinapinic acid matrix (Ciphergen Biosystems, US) in 0.5% trifluoroacetic acid and 50% acetonitrile was added on each spot and air-dried for further analysis. The protein chips were analyzed using SELDI ProteinChip System 4000 Mass spectrometer (Ciphergen Biosystems, US) and the data were analyzed with Ciphergen Express software, version 3.0 (Ciphergen Biosystems, US). After collecting all the raw data automatically with protein peaks ranging from 2000 to 35000 Da, the data was further normalized to total ion current and aligned. These analyses included automatic peak detection, baseline subtraction and mass accuracy calibration.
To assess machine reproducibility, quality control (QC) serum sample, collected from a healthy volunteer (EK), was applied onto different spots on every chip run. In these spectra, several independent control peaks were identified to calculate the CV (coefficient of variance) of intensity and CV of m/z in intra-assay and inter-assay.
Statistical Analysis
Protein peaks of all sample spectra were clustered with the Ciphergen Express software, version 3.0, performing Expression Difference Mapping. Autodetect peaks labeling was achieved in all spectra with 5.0 S/N (signal to noise ratio), 3 valley depth for the first pass, minimal peak threshold: 20% of all spectra and 3.0 S/N, 1 valley depth for the second pass, with 0.3% cluster mass window, and the estimated peaks were added. Proteomic peak features that differed significantly between groups were identified using the Mann-Whitney nonparametric test. To determine the best discriminative proteomic index, area under receiver operating characteristics curves (AUROC) was used as a measurement. Statistically significant discriminatory peaks between groups were determined with AUROC ≥0.8 and p<0.05. Comparison between patients with advanced (F2, F3, F4) and lowgrade fibrosis (F0, F1) was also performed using tree classification (cross-validation) depending on peak intensity with the Biomarker Patterns software (BPS), version 5.0 (Ciphergen Biosystems). Briefly, the classification tree split the data into two nodes using one rule at a time in the form of peak intensity. The splitting decisions were based on the normalized intensity levels of peaks. The process of splitting was continued until terminal nodes were reached.
RESULTS
Reproducibility of the SELDI system
The reproducibility of the SELDI system was tested using 4 peaks from a QC sample. For all peaks, the CV for mass accuracy was 0.07%. The CVs calculated for intra-assay and inter-assay intensities were 27% and 30%, respectively.
Identification of Fibrosis-Associated Proteomic Features
A total of 168 proteomic peaks were generated. Among them, 6 peaks had mean values of intensity that differed significantly between patients with advanced fibrosis and those with no or mild fibrosis, and 15 peaks differed significantly between patients with advanced fibrosis and HCs. The number of discriminatory peaks between different stages of liver fibrosis with AUROC ≥0.8 and p<0.05 are shown in Table 1 . When analysis was performed between F0, F1 and F2 groups separately, no statistically discriminatory peak was evident (Table 1 ). There was also no significant difference observed in the analysis of the HC and lowgrade fibrosis groups (F0 or F1) . However, the comparison between F3 and F2 or between F3 and F4 revealed 6 and 35 statistically significant proteomic features, respectively (Table 1) . Among the former 6 proteomic features, which were discriminative between F3 and F2 (Table 2) The number of discriminatory peaks between patients with cirrhosis and different stages of fibrosis, including mild fibrosis (F0 or F1) and F2 or F3 groups, are given in Table 3 . A total of 26 statistically significant discriminatory proteomic features between patients with cirrhosis and F2 or F3 are listed in Table 4 . In Figure 1 , SELDI-TOF spectra of patients with cirrhosis (F4), F2 and F3 are shown for the most discriminatory peak of 9183 m/z, with an AUROC and p value of 0.92 and 1.54 x 10 -5
, respectively.
The comparison between patients with low-grade fibrosis (F0, F1) and advanced fibrosis (F2, F3, F4) revealed 6 discriminatory proteomic features with m/z of 4280, 3768, 3952, 9495, 4642, and 11838 Da ( Table 5 ). The expression levels of 3 of these highly significantly discriminatory proteomic features with m/z 4280, 3768 and 3952 are shown in Figure 2. Among these, the peaks with 4280 m/z and 3952 m/z were also found to be discriminatory for HC vs. F2, both giving AUROC value of 0.8 and p values of 0.01 and 0.02, respectively (data not shown). The visual comparison of intensities of these 3 peaks between fibrosis stages are shown as a box plot display in Figure 3 . With the help of BPS, a decision tree classification with 4 terminal nodes was created to separate low-grade and advanced fibrosis (Figure 4) . The root node of the decision tree includes the most important protein peak with an m/z of 4280 Da, which was also determined as statistically the most discriminatory single peak in the present study. If the intensity of the peak 4280 m/z was lower or equal to 18.086 and 10453 m/z was lower or equal to 0.667, these samples split into terminal 
DISCUSSION
In this study, serum proteome differences in different liver fibrosis stages were investigated. No statistically significant discriminatory peaks were found that would differentiate between F0, F1 and F2 fibrosis (Table 1) , in line with numerous data on fibrosis markers in patients with chronic viral hepatitis. This is not surprising, since quantification of fibrosis by image analysis revealed that an increase in the area of fibrosis is rather subtle until F2 fibrosis (6) . Thus, expectedly in both chronic hepatitic C and B, several biochemical and fibrosis markers could more or less reliably differentiate mild fibrosis from advanced fibrosis. However, the area of fibrosis detected by image analysis was found to increase by almost three-fold from F2 to F3 fibrosis and about five-fold from F2 to F4 fibrosis (6) . Thus, aiming for a marker that would differentiate F1 fibrosis from F0 or F2 fibrosis may scientifically not be realistic. However, searching for a marker that would differentiate not only advanced fibrosis from mild fibrosis but also F3 fibrosis from F2 or F4 appears to be reasonable from a scientific perspective. Indeed, in this study, we were able to find such proteomic peaks. . These data have practical value in the clinic and need confirmation with other studies, due to the low numbers of patients in the F2 and F3 groups in our study.
The comparison between cirrhosis and mild fibrosis revealed 46 discriminatory peaks. Of these 46 peaks, 15 showed higher and 31 showed lower intensity in patients with cirrhosis. The number of discriminatory peaks for cirrhosis and significant fibrosis of stage F2 or F3 was 26. These results showed that there are statistically significant differences even between serum proteomes of cirrhotic patients and significant fibrosis (F2 or F3).
A few other studies have looked at identifying serum proteomic signatures associated with liver fibrosis and cirrhosis using SELD-TOF MS. Zhu et al. (22) explored serum protein spectra of 25 patients with HBV-induced liver cirrhosis and 45 non-cirrhotic samples using CM10 protein chips (22) . They reportedly were able to predict cirrhosis with 80% (24) reported eight independent SELDI proteomic features to be discriminative between patients with no or mild fibrosis (F0, F1) and those of patients with advanced fibrosis (F2, F3, F4 ). In the same study, a proteomic index with the combination of these eight proteomic features was created using multivariate logistic regression. This index showed high accuracy for predicting advanced fibrosis, with an AUROC of 0.88. In our study, we generated a decision tree to identify multi serum protein pattern for differentiation of mild (F0, F1) and advanced fibrosis (F2, F3, F4) using cross-validation with the help of BPS. This model revealed triple proteomic features with 4280, 10453 and 6376 Da, yielding a sensitivity of 83.3%, a specificity of 85.1%, a positive predictive value of 81.1%, and a negative predictive value of 86.9%.
Comparing the results of the present study with the above-mentioned studies, there was no discriminatory peak with same molecular mass. This is also the case when comparing the results of the above-mentioned studies to each other. This contradiction may be explained by the use of different protein chips (CM10 vs. IMAC) for our study and one important caveat inherent to all studies, namely the small sample sizes investigated. This is no doubt also a drawback of the current study. Further, we included patients with both HBV-and HCV-induced liver disease. In addition, different methodologies of data analysis may explain the variability.
In conclusion, the results revealed discriminatory peaks between cirrhosis and other stages of liver fibrosis, but beyond that, peaks that were able to discriminate F2 from F3 and F3 from F4 fibrosis. The triple proteomic peaks consisting of 4280 Da, 10453 Da and 6376 Da reliably discriminate mild stage from advanced fibrosis with high sensitivity and specificity. These discriminating peaks are candidate biomarkers that need to be validated with a significant number of patients.
